DZ

Daniel Zagury

NE Neovacs: 17 patents #1 of 21Top 5%
CN CNRS: 2 patents #1,756 of 11,908Top 15%
UC Université Paris Cité: 1 patents #123 of 608Top 25%
U7 Université Paris Diderot—Paris 7: 1 patents #80 of 323Top 25%
Overall (All Time): #160,601 of 4,157,543Top 4%
25
Patents All Time

Issued Patents All Time

Patent #TitleCo-InventorsDate
12024558 Method of inhibiting HIV-1 viral rebound in a subject using interferon inhibitors and ART 2024-07-02
11957748 Vaccine to pathogenic immune activation cells during infections 2024-04-16
11365392 Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof Helene Le Buanec, Sophie Duchez, Valerie Schiavon, Armand Bensussan 2022-06-21
11198851 Ex vivo generation of γδ Foxp3+ regulatory T cells and therapeutic uses thereof Helene Le Buanec, Sophie Duchez, Valerie Schiavon, Armand Bensussan 2021-12-14
11077185 Vaccine to pathogenic immune activation cells during infections 2021-08-03
10632186 Vaccine to pathogenic immune activation cells during infections 2020-04-28
8697047 Stable immunogenic product comprising antigenic heterocomplexes Helene Le Buannec 2014-04-15
8679483 High-yield method for the production of human antibodies blocking the biological activity of a human cytokine Bernard Bizzini, Helene Le Buanec 2014-03-25
8372388 Method for preparing a stable TNF-α vaccine Helene Le Buanec 2013-02-12
8101165 Use of immunogens to treat or prevent, in malignant tumors, the immune or vascular disorders induced by extracellular factors Jean-Francois Zagury, Bernard Bizzini, Helene Le Buanec 2012-01-24
7972603 Stable immunogenic product comprising antigenic heterocomplexes Helene Le Buannec 2011-07-05
7887811 Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein Helene Le Buanec 2011-02-15
7504479 Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses Jean-Francois Zagury 2009-03-17
7351554 Use of inactive immunosuppressive and/or angiogenic immunogenic proteins, for producing secretory IgA's 2008-04-01
7314629 Non-immunosuppressive immunogenic or vaccine composition comprising a mutated E7 protein of the HPV-16 virus Helene Le Buanec, Bernard Bizzini 2008-01-01
7208148 Chemically modified cytokines Jean-Francois Zagury 2007-04-24
7067246 Method for determining prognosis of HIV infected individuals Jean-Francois Zagury 2006-06-27
7022482 Use of immunogenic immunosuppressive and/or angiogenic proteins which have been rendered inactive, process for their preparation and pharmaceutical or vaccinal uses Jean-Francois Zagury 2006-04-04
7015016 Use of inactivated immunosuppressive or angiogenic immunogenic proteins for producing secretory IgA's 2006-03-21
6878370 Chemically modified TNF-α Jean-Francois Zagury 2005-04-12
6455045 Immunogenic compounds with in particular an anti-cytokine effect, preparation process, pharmaceutical compositions and kits containing them Jean-Francois Zagury, Bernard Bizzini 2002-09-24
6228890 Use of alicyclic diamines as immunomodulators Jean-Claude Maziere, Amar Achour, Jean-Charles Landureau 2001-05-08
6200575 Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them Jean-Francois Zagury, Bernard Bizzini 2001-03-13
6132721 Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same Jean-Francois Zagury, Bernard Bizzini 2000-10-17
6093405 Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines Jean-Francois Zagury, Bernard Bizzini 2000-07-25